ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,267.84
-0.74%
Dow Jones
39,065.26
-1.53%
US Dollar vs MXN
16.7223
-0.06%
Brent Oil
81.225
-0.10%
Bitcoin
67,557.74
-0.54%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Oric Pharmaceuticals Inc (ORIC)

  7. Oric Pharmaceuticals Inc (ORIC) Noticias

ORIC

Oric Pharmaceuticals (ORIC)

Oric Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ORIC
FechaHoraFuenteTítuloSímboloCompañía
06/05/202415:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORICOric Pharmaceuticals Inc
06/05/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORICOric Pharmaceuticals Inc
06/05/202415:05GlobeNewswire Inc.ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational UpdatesNASDAQ:ORICOric Pharmaceuticals Inc
03/05/202415:30GlobeNewswire Inc.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ORICOric Pharmaceuticals Inc
15/04/202415:15GlobeNewswire Inc.ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLCNASDAQ:ORICOric Pharmaceuticals Inc
08/04/202407:00GlobeNewswire Inc.ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:ORICOric Pharmaceuticals Inc
05/04/202415:30GlobeNewswire Inc.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ORICOric Pharmaceuticals Inc
04/04/202415:30GlobeNewswire Inc.ORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:ORICOric Pharmaceuticals Inc
11/03/202416:28Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ORICOric Pharmaceuticals Inc
11/03/202415:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ORICOric Pharmaceuticals Inc
11/03/202415:05GlobeNewswire Inc.ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational UpdatesNASDAQ:ORICOric Pharmaceuticals Inc
06/03/202415:30GlobeNewswire Inc.ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma ConferenceNASDAQ:ORICOric Pharmaceuticals Inc
05/03/202415:30GlobeNewswire Inc.ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:ORICOric Pharmaceuticals Inc
14/02/202415:30GlobeNewswire Inc.ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership SummitNASDAQ:ORICOric Pharmaceuticals Inc
04/02/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORICOric Pharmaceuticals Inc
30/01/202411:12Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ORICOric Pharmaceuticals Inc
26/01/202415:58Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ORICOric Pharmaceuticals Inc
25/01/202412:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ORICOric Pharmaceuticals Inc
22/01/202407:30GlobeNewswire Inc.ORIC Pharmaceuticals Announces $125 Million Private Placement FinancingNASDAQ:ORICOric Pharmaceuticals Inc
08/01/202407:30GlobeNewswire Inc.ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming MilestonesNASDAQ:ORICOric Pharmaceuticals Inc
02/01/202415:30GlobeNewswire Inc.ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ORICOric Pharmaceuticals Inc
11/12/202311:00GlobeNewswire Inc.Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination DevelopmentNASDAQ:ORICOric Pharmaceuticals Inc
06/11/202315:10GlobeNewswire Inc.ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational UpdatesNASDAQ:ORICOric Pharmaceuticals Inc
02/11/202308:00GlobeNewswire Inc.ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:ORICOric Pharmaceuticals Inc
21/10/202306:30GlobeNewswire Inc.Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class ProfileNASDAQ:ORICOric Pharmaceuticals Inc
17/10/202315:30GlobeNewswire Inc.ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023NASDAQ:ORICOric Pharmaceuticals Inc
20/09/202315:30GlobeNewswire Inc.ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:ORICOric Pharmaceuticals Inc
10/08/202315:05GlobeNewswire Inc.ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational UpdatesNASDAQ:ORICOric Pharmaceuticals Inc
04/08/202315:30GlobeNewswire Inc.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ORICOric Pharmaceuticals Inc
28/06/202318:19Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ORICOric Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ORIC

Su Consulta Reciente

LSE
32UL
Hsbc Bk. 24
USOTC
PIFYF
Pine Cliff Energy (QX)
USOTC
GDHLF
GDS (PK)
ASX
MNBR
COIN
TSHPUST
12Ships
ASX
YRLN
Yandal Resources
NASDAQ
GPRAGX
Putnam Retirement Advant...
LSE
FJPU
Ft Jap Adex
LSE
47SZ
Investec 24
USOTC
PAFRY
Pan African Resources (QX)
LSE
AI35
Hsbc Bk.25
NASDAQ
STCN
Steel Connect
USOTC
PSNTF
Personal Assets (PK)
USOTC
HNHPF
Hon Hai Precision Indust... (PK)
COIN
WETHUST
TSX
ZUVE
BMO US Equity Value MFR
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados